Will gut microbiota help design the next generation of GLP1-based therapies for type 2 diabetes?

Lists

Download

Full text not archived in this repository.

Tools

Claus, S. P. (2017) Will gut microbiota help design the next generation of GLP1-based therapies for type 2 diabetes? Cell Metabolism, 26 (1). pp. 6-7. ISSN 1550-4131 doi: 10.1016/j.cmet.2017.06.009

Abstract/Summary

Glucagon-like peptide one (GLP-1)-based therapies for reducing hyperglycemia in type 2 diabetic patients are efficient, though some individuals develop GLP-1 resistance. In a recent issue of Cell Metabolism, Grasset et al. (2017) demonstrated that GLP-1 sensitivity is modulated by gut bacteria through NO signaling in the enteric nervous system.

Altmetric Badge

Item Type	Article
URI	https://reading-clone.eprints-hosting.org/id/eprint/73545
Item Type	Article
Refereed	Yes
Divisions	Life Sciences > School of Chemistry, Food and Pharmacy > Department of Food and Nutritional Sciences > Food Microbial Sciences Research Group
Publisher	Elsevier
Download/View statistics	View download statistics for this item

Funded Project

Funders:	Medical Research Council	The sponsoring bodies who contributed funding for the creation of this item. Example: NERC Example: The Royal Society of Chemistry A pick list of funders may appear as you type in the funder's name in full or as an acronym. Select a correct match to complete the field or type in a new entry in full. For new entries, the full name is preferred.
Projects:	High resolution systems biology to determine the role of gut microbiota on type 2 diabetes Funded by: Medical Research Council (MR/M004945/1 - £521,975) Local Lead (PI): Sandrine Claus 1 January 2015 - 31 December 2017	Click Add to select your project (received at Reading) from an autocomplete list.

Deposit Details

Date Deposited:	13 Nov 2017 12:24	Date item deposited into CentAUR
Last Modified:	07 Feb 2025 02:33	Date item last modified

University Staff: Request a correction | Centaur Editors: Update this record

Search Google Scholar